Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 419

    1.

    Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways.

    Dalenc F, Giamarchi C, Petit M, Poirot M, Favre G, Faye JC.

    Breast Cancer Res. 2005;7(6):R1159-67. Epub 2005 Nov 21.

    PMID:
    16457696
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.

    Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.

    Anticancer Res. 2006 May-Jun;26(3A):1773-84.

    PMID:
    16827106
    [PubMed - indexed for MEDLINE]
    3.

    Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells.

    Kallio A, Zheng A, Dahllund J, Heiskanen KM, Härkönen P.

    Apoptosis. 2005 Dec;10(6):1395-410.

    PMID:
    16215679
    [PubMed - indexed for MEDLINE]
    4.

    [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].

    Zhen LL, Zhu X, Zheng W, Wang XY, Wu ZY.

    Ai Zheng. 2006 Jul;25(7):839-43. Chinese.

    PMID:
    16831274
    [PubMed - indexed for MEDLINE]
    Free Article
    6.

    Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.

    Treeck O, Wackwitz B, Haus U, Ortmann O.

    Gynecol Oncol. 2006 Aug;102(2):292-9. Epub 2006 Jan 26.

    PMID:
    16443261
    [PubMed - indexed for MEDLINE]
    7.

    Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen.

    Zheng A, Kallio A, Härkönen P.

    Endocrinology. 2007 Jun;148(6):2764-77. Epub 2007 Mar 15. Erratum in: Endocrinology. 2007 Aug;148(8):3931.

    PMID:
    17363451
    [PubMed - indexed for MEDLINE]
    Free Article
    8.

    Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen.

    Chen J, Power KA, Mann J, Cheng A, Thompson LU.

    Exp Biol Med (Maywood). 2007 Sep;232(8):1071-80.

    PMID:
    17720953
    [PubMed - indexed for MEDLINE]
    Free Article
    9.

    Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells.

    Perry RR, Kang Y, Greaves B.

    Ann Surg Oncol. 1995 May;2(3):238-45.

    PMID:
    7641021
    [PubMed - indexed for MEDLINE]
    10.

    [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].

    Bachmann-Moisson N, Barberi-Heyob M, Merlin JL, Ledrich ML, Batt AM, Guillemin F.

    Bull Cancer. 1996 Oct;83(10):808-15. Review. French.

    PMID:
    8952630
    [PubMed - indexed for MEDLINE]
    11.

    Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.

    Johnston SR, Boeddinghaus IM, Riddler S, Haynes BP, Hardcastle IR, Rowlands M, Grimshaw R, Jarman M, Dowsett M.

    Cancer Res. 1999 Aug 1;59(15):3646-51.

    PMID:
    10446976
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

    Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.

    Breast Cancer Res. 2007;9(4):R50.

    PMID:
    17686159
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    13.

    Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.

    Obrero M, Yu DV, Shapiro DJ.

    J Biol Chem. 2002 Nov 22;277(47):45695-703. Epub 2002 Sep 19.

    PMID:
    12244117
    [PubMed - indexed for MEDLINE]
    Free Article
    14.

    Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.

    Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, Goldfine ID.

    J Cell Biochem. 2008 Feb 1;103(2):624-35.

    PMID:
    17562544
    [PubMed - indexed for MEDLINE]
    15.

    Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells.

    Kang Y, Cortina R, Perry RR.

    J Natl Cancer Inst. 1996 Mar 6;88(5):279-84.

    PMID:
    8614006
    [PubMed - indexed for MEDLINE]
    Free Article
    16.

    Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1.

    Liang Y, Hou M, Kallab AM, Barrett JT, El Etreby F, Schoenlein PV.

    Int J Oncol. 2003 Aug;23(2):369-80.

    PMID:
    12851686
    [PubMed - indexed for MEDLINE]
    17.

    Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.

    Kijima I, Itoh T, Chen S.

    J Steroid Biochem Mol Biol. 2005 Dec;97(4):360-8. Epub 2005 Nov 2.

    PMID:
    16263272
    [PubMed - indexed for MEDLINE]
    18.

    Effects of tamoxifen on human squamous cell carcinoma lines of the head and neck.

    Hoffmann TK, Bojar H, Eckel J, van Lierop A, Balz V, Friebe-Hoffmann U, Hauser U, Bier H.

    Anticancer Drugs. 2002 Jun;13(5):521-31.

    PMID:
    12045464
    [PubMed - indexed for MEDLINE]
    19.

    Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism.

    de Medina P, Payré B, Boubekeur N, Bertrand-Michel J, Tercé F, Silvente-Poirot S, Poirot M.

    Cell Death Differ. 2009 Oct;16(10):1372-84. Epub 2009 Jun 12.

    PMID:
    19521424
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.

    Kim R, Tanabe K, Emi M, Uchida Y, Osaki A, Toge T.

    Int J Oncol. 2005 Apr;26(4):1025-31.

    PMID:
    15753998
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk